A great deal of evidence has indicated that SGLT-2 inhibitors have strong effects on body weight in patients with diabetes mellitus and can be used as potential agents for obesity management (9, 10). This evidence concerns the gene SLC5A2 and obesity due to melanocortin 4 receptor deficiency.